Blog Listing

ZymeWorks – Recent IPO that could be synonymous with ‘Best-in-class’

  • Newly IPO’d Zymeworks promises to design ‘”best in class” antibody and protein therapeutics.
  • Using bioinformatics and computational design, the company is targeting HER2-cancer therapies with ZW25 and ZW33.
  • An impressive list of collaborations has potential milestones far above $1 billion.
  • Early stage gives plenty of time to keep watch on ZYME.
  • We’re not yet committed to buying the stock, but placing it on watch.

To read the full article, click here.


Leave a Reply